Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. (0R1D.L) Financial Performance & Income Statement Overview
Review Sangamo Therapeutics, Inc. (0R1D.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Sangamo Therapeutics, Inc. (0R1D.L) Income Statement & Financial Overview
Analyze Sangamo Therapeutics, Inc.’s 0R1D.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $6.44M | $7.55M | $49.41M | $356000.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $2.57M |
| Gross Profit | $6.44M | $7.55M | $49.41M | -$2.22M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | -$6.23 |
| R&D Expenses | $26.006M | $23.68M | $27.73M | $24.22M |
| SG&A Expenses | $10.06M | $9.87M | $11.05M | $12.04M |
| Operating Expenses | $36.06M | $33.54M | $38.78M | $37.44M |
| Total Costs & Expenses | $36.06M | $33.54M | $38.78M | $37.44M |
| Interest Income | $309000.00 | $2.17M | $129000.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.92M | $2.13M | $2.13M | $2.57M |
| EBITDA | -$27.70M | -$23.86M | $12.76M | -$33.34M |
| EBITDA Ratio | -$4.30 | -$3.16 | $0.26 | -$93.65 |
| Operating Income | -$29.63M | -$25.99M | $10.63M | -$37.08M |
| Operating Income Ratio | -$4.60 | -$3.44 | $0.22 | -$104.17 |
| Other Income/Expenses (Net) | -$850000.00 | $2.17M | $129000.00 | $1.03M |
| Income Before Tax | -$30.48M | -$23.82M | $10.76M | -$36.05M |
| Income Before Tax Ratio | -$4.73 | -$3.15 | $0.22 | -$101.28 |
| Income Tax Expense | $119000.00 | -$427000.00 | $88000.00 | $74000.00 |
| Net Income | -$30.60M | -$23.40M | $10.67M | -$36.13M |
| Net Income Ratio | -$4.75 | -$3.10 | $0.22 | -$101.48 |
| EPS | -$0.14 | -$0.11 | $0.05 | -$0.18 |
| Diluted EPS | -$0.14 | -$0.11 | $0.04 | -$0.18 |
| Weighted Avg Shares Outstanding | $220.27M | $210.19M | $208.34M | $203.95M |
| Weighted Avg Shares Outstanding (Diluted) | $220.27M | $210.19M | $214.32M | $203.95M |
Over the past four quarters, Sangamo Therapeutics, Inc. demonstrated steady revenue growth, increasing from $356000.00 in Q2 2024 to $6.44M in Q1 2025. Operating income reached -$29.63M in Q1 2025, maintaining a consistent -460% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$27.70M, reflecting operational efficiency. Net income dropped to -$30.60M, with EPS at -$0.14. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan